Expression and clinical value of EIF3CL in serous ovarian cancer.

IF 1.4 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Journal of International Medical Research Pub Date : 2025-05-01 Epub Date: 2025-05-26 DOI:10.1177/03000605251340320

Tingting Li, Longyang Liu, Qudi Qiao, Zhongqiu Lin, Jianhuan Yuan, Zhaoyang Zeng, Jilong Yao

{"title":"Expression and clinical value of EIF3CL in serous ovarian cancer.","authors":"Tingting Li, Longyang Liu, Qudi Qiao, Zhongqiu Lin, Jianhuan Yuan, Zhaoyang Zeng, Jilong Yao","doi":"10.1177/03000605251340320","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectivesThis study aimed to explore the expression of eukaryotic translation initiation factor 3 subunit C-like in serous ovarian cancer samples (both paraffin-embedded and fresh samples) and evaluate its clinical value in patients with serous ovarian cancer.MethodsTwenty-five fresh serous ovarian cancer tissues and their paired paratumor tissues were subjected to reverse transcription-quantitative polymerase chain reaction assay to detect eukaryotic translation initiation factor 3 subunit C-like messenger RNA expression. In addition, 135 paraffin-embedded serous ovarian cancer samples and 36 paratumor samples were assessed for eukaryotic translation initiation factor 3 subunit C-like protein expression using immunohistochemistry.ResultsBoth protein and messenger RNA expression levels of eukaryotic translation initiation factor 3 subunit C-like were higher in serous ovarian cancer samples than in paratumor samples, and its high expression was associated with poor overall survival in patients with serous ovarian cancer. In addition, multivariate Cox regression analysis showed that high expression of eukaryotic translation initiation factor 3 subunit C-like was an independent poor prognostic factor for patients with serous ovarian cancer.ConclusionsEukaryotic translation initiation factor 3 subunit C-like is upregulated in serous ovarian cancer samples, and it may be recommended as a useful poor prognostic biomarker in patients with serous ovarian cancer.</p>","PeriodicalId":16129,"journal":{"name":"Journal of International Medical Research","volume":"53 5","pages":"3000605251340320"},"PeriodicalIF":1.4000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106975/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of International Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03000605251340320","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/26 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

ObjectivesThis study aimed to explore the expression of eukaryotic translation initiation factor 3 subunit C-like in serous ovarian cancer samples (both paraffin-embedded and fresh samples) and evaluate its clinical value in patients with serous ovarian cancer.MethodsTwenty-five fresh serous ovarian cancer tissues and their paired paratumor tissues were subjected to reverse transcription-quantitative polymerase chain reaction assay to detect eukaryotic translation initiation factor 3 subunit C-like messenger RNA expression. In addition, 135 paraffin-embedded serous ovarian cancer samples and 36 paratumor samples were assessed for eukaryotic translation initiation factor 3 subunit C-like protein expression using immunohistochemistry.ResultsBoth protein and messenger RNA expression levels of eukaryotic translation initiation factor 3 subunit C-like were higher in serous ovarian cancer samples than in paratumor samples, and its high expression was associated with poor overall survival in patients with serous ovarian cancer. In addition, multivariate Cox regression analysis showed that high expression of eukaryotic translation initiation factor 3 subunit C-like was an independent poor prognostic factor for patients with serous ovarian cancer.ConclusionsEukaryotic translation initiation factor 3 subunit C-like is upregulated in serous ovarian cancer samples, and it may be recommended as a useful poor prognostic biomarker in patients with serous ovarian cancer.

查看原文本刊更多论文

EIF3CL在浆液性卵巢癌中的表达及临床价值

目的探讨真核翻译起始因子3亚单位c样在浆液性卵巢癌（石蜡包埋和新鲜样品）中的表达，并评价其在浆液性卵巢癌患者中的临床价值。方法采用逆转录-定量聚合酶链反应法检测25例新鲜浆液性卵巢癌组织及其配对瘤旁组织中真核翻译起始因子3亚基c样信使RNA的表达。此外，利用免疫组织化学方法检测135例石蜡包埋浆液性卵巢癌和36例准肿瘤样本真核翻译起始因子3亚单位c样蛋白的表达。结果真核翻译起始因子3亚基c样蛋白和信使RNA在浆液性卵巢癌患者中的表达水平均高于准肿瘤患者，其高表达与浆液性卵巢癌患者的总生存率较低有关。此外，多因素Cox回归分析显示真核翻译起始因子3亚基c样的高表达是浆液性卵巢癌患者预后不良的独立因素。结论真核翻译起始因子3亚单位c样在浆液性卵巢癌中表达上调，可作为浆液性卵巢癌患者预后不良的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of International Medical Research 医学-药学

CiteScore

3.20

自引率

0.00%

发文量

555

审稿时长

1 months

期刊介绍： _Journal of International Medical Research_ is a leading international journal for rapid publication of original medical, pre-clinical and clinical research, reviews, preliminary and pilot studies on a page charge basis. As a service to authors, every article accepted by peer review will be given a full technical edit to make papers as accessible and readable to the international medical community as rapidly as possible. Once the technical edit queries have been answered to the satisfaction of the journal, the paper will be published and made available freely to everyone under a creative commons licence. Symposium proceedings, summaries of presentations or collections of medical, pre-clinical or clinical data on a specific topic are welcome for publication as supplements. Print ISSN: 0300-0605